Latest California Healthline Stories
New Medicare Advantage Plans Tailor Offerings to Asian Americans, Latinos, and LGBTQ+
As more seniors opt for Medicare Advantage, a few small insurers have begun offering plans that provide culturally targeted benefits for cohorts including Asian Americans, Latinos, and LGBTQ+ people. The approach, policy researchers say, has potential and perils.
Florida Foster Kids Are Given Powerful Medications, but Feds Find State Oversight Lacking
A report by the U.S. Department of Health and Human Services raises troubling questions about the use of powerful medications within Florida’s child welfare system and the risk of overdoses or dangerous side effects if children are given the wrong combination of drugs.
Nuevos planes de Medicare Advantage adaptan ofertas para asiáticos, latinos y LGTBQ+
A medida que Medicare Advantage gana popularidad entre los adultos mayores, tres compañías del sur de California están lanzando nuevos planes que se enfocan en comunidades culturales y étnicas, con ofertas especiales y profesionales que hablan su idioma nativo.
Massive Kaiser Permanente Strike Looms as Talks Head to the Wire
Both sides, still at loggerheads over pay and staffing, agreed to keep bargaining after unions announced a possible strike Oct. 4-7. If no deal is reached, a walkout by about 75,000 KP workers in five states could disrupt care.
Biden Administration to Ban Medical Debt From Americans’ Credit Scores
The White House said the Consumer Financial Protection Bureau will develop new regulations that would prevent unpaid medical bills from being counted on credit reports.
KFF Health News' 'What the Health?': Countdown to Shutdown
Congress appears to be careening toward a government shutdown, as a small band of House conservatives vow to block any funding for the fiscal year that begins Oct. 1 unless they win deeper cuts to health and other domestic programs. Meanwhile, former President Donald Trump continues to roil the GOP presidential primary field, this time with comments about abortion. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Tami Luhby of CNN join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Also, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.
Resurge la hepatitis C, ¿podrá el plan de Biden eliminar este viejo flagelo en cinco años?
Se calcula que el 40% de los más de 2 millones de personas con hepatitis C en Estados Unidos ni siquiera saben que la tienen, pero el virus puede estar dañando silenciosamente su hígado, causando cicatrices, insuficiencia hepática o cáncer de hígado.
Hep C’s Number Comes Up: Can Biden’s 5-Year Plan Eliminate the Longtime Scourge?
Before covid-19, hepatitis C held the distinction of claiming more American lives each year than any other infectious disease — that’s despite the marketing of several relatively affordable, highly effective treatments.
Save Billions or Stick With Humira? Drug Brokers Steer Americans to the Costly Choice
Thousands of patients with autoimmune diseases who rely on Humira, with a list price of $6,600 a month, could get financial relief from new low-cost rivals. So far, the pharmacy benefit managers that control drug prices in America have not delivered on those savings.
Humira lleva 20 años disfrutando de una exclusividad muy cara en el país. Sus competidores podrían ahorrarle al sistema sanitario $9,000 millones.